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Leishmania are digenetic protozoa, alternating between the promastigote, a 
free-living flagellate in the gut of the vector sandfly, and the amastigote, the 
obligatory intracellular form which resides in phagolysosomes of mammalian 
macrophages. Infection with this organism begins with the recognition of the 
host macrophage by the promastigotes, attachment and uptake by 'facilitated 
phagocytosis' [1]. The basic lesion in leishmaniasis is the infected macro-
phage. The infected macrophage displays parasite antigens on its surface 
(reviewed in [9]) and there is no reason why these should not be recognized 
by T cells in an MHC restricted manner. 
Leishmania major infection of mice produces a range of disease patterns, 
similar to the situation in man, depending on the strain of inbred mouse. 
However, hypothymic nude mice of both resistant and susceptible genotypes 
are highly susceptible, suggesting a role for T cell-dependent immunity in 
resistance to disease [3, 11]. 
In response to L. major infection, both delayed-type hypersensitivity 
(DTH) and antibodies are produced (reviewed in [11]). However, there 
appears to be no strict correlation between healing and development of cell-
mediated immune responses, and progressive lesions may develop in the 
presence of DTH to crude antigen mixtures [11]. Animals of resistant geno-
types recover from infection and are resistant to reinfection [9,11]. Protection 
can be transferred with L3T4+, Ly2- T cells to syngeneic recipients [11]. 
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Vaccination against cutaneous leishmaniasis is feasible with crude antigens 
[reviewed in ref. 11]. The ideal vaccine would be a molecularly defined 
set of antigens, either involved in the induction of host-protective immune 
responses or critical to parasite uptake into the macrophage. We have focused 
on the characterization of the parasite molecules involved in recognition and 
uptake into host macrophages as potential vaccine candidates. Using the 
monoclonal antibody WIC-79.3, we have recently described an externally 
oriented, amphipathic membrane antigen of L. major which is shed into 
culture medium [5, 6]. This antigen had been shown previously to be part 
of a polymorphic family of carbohydrate antigens present in all Leishmania. 
Each antigen was shown to be species-specific and this has formed the basis 
for a serotyping system for the classification and diagnosis of leishmaniasis 
[17]. 
While the structure of this molecule in L. major is still unknown, and an 
area of considerable interest, it appears from our data that the molecule is 
anchored into the parasite membrane by covalently attached fatty acid. It 
contains sulphated and phosphated sugars, with galactose in a terminal 
position, accessible for recognition by ricin lectin and radio labelled by 
[3H] sodium borohydride following galactose oxidase treatment [6]. A similar 
molecule has been identified in L. donovani and partially characterized by 
Turco et al. [18]. Preliminary data indicate that it may be similar in structure 
to bacteriallipopolysaccharides (S. J. Turco, personal communication). 
Our studies examining the biological function of this glycolipid, or lipopoly-
saccharide molecule, indicate that it binds specifically to macrophages in vitro 
[6]. In addition, antibodies to the carbohydrate moiety block attachment of 
promastigotes to macrophages. Taken together, our data suggest that the L. 
major glycolipid is involved in macrophage recognition and attachment, and 
that this interaction occurs via the carbohydrate part of the molecule. Inter-
estingly, the presence of this molecule, or parts of it, on the surface of 
infected macrophages can be inferred from immunofluorescence studies using 
monoclonal antibodies [2, 4]. Consequently, this antigen is biologically 
important as a recognition molecule, and immunologically important because 
of its expression on the surface of the infected macrophage, available for T-
cell recognition. 
Mice immunized with the glycolipid antigen purified from detergent lysates 
of L. major promastigotes using the monoclonal antibody WIC-79.3 (i.e. L-
LPS) are resistant to subsequent infection with L. major [7, 8]. When injected 
with L-LPS plus the adjuvant, killed Corynebacterium parvum, intraperitone-
ally, mice of healer phenotype (e.g. C3H/He, C57BLl6) may be totally 
resistant in terms of lesion development. Doses used have been in the range 
of 2-10 fLg L-LPS and 100-200 fLg C. parvum. Immunized mice of non-healer 
phenotype (BALB/c and BALB/c H-2 congenic mice) generally show a 
delayed appearance of lesions and/or lesions that remain small in size. As 
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with crude antigen mixtures (including attenuated whole organisms), with or 
without adjuvants [7, 10, 12, 13], subcutaneous injections fail to induce 
resistance to disease in mice. The nature of this peculiar constraint imposed 
by route of injection remains unknown; it is also unknown whether it pertains 
to man. 
No protective effect in mice has yet been demonstrated with the carbo-
hydrate portion (CHO) of L-LPS prepared from promastigote culture super-
natants and injected by any route, with any adjuvant or in any amount. In 
fact, CHO injected with Freund's complete adjuvant (FCA) will increase the 
duration of subsequent disease in C3H/He and C57BLl6 mice [S, 15] chal-
lenged with L. major promastigotes. Moreover, it can be shown readily be 
adoptive transfers in nude mice that BALB/c mice injected with CHO plus 
FCA have an increased frequency of disease-promoting ('suppressor') cells 
in their lymphoid organs [15]. Using in vivo titrations in BALB/c nu/nu 
mice, the frequency of disease-promoting cells (that from all other evidence 
in the cutaneous leishmaniasis-mouse system are likely to be Ly2- T cells) 
is increased by about 10. Other unpublished and preliminary data suggest 
that injections of FCA plus the CHO purified from L. donovani culture 
supernatants, by affinity chromatography on monoclonal antibody WIC-lOS.3 
increase the susceptibility of C3H/He mice to L. major. Thus there may be 
a sharing of 'disease-promoting epitopes' between the carbohydrate moiety 
of the L-LPS of these two leishmania species. 
We have proposed [14, 16] that L3T4+ Ly2- T-cell recognition of L-
LPS, oriented in the membrane of infected macrophages through its lipid 
component, results in the release of mediators of macrophage activation 
(such as INF--y and others) with subsequent parasitostatic, if not parasito-
cidal, effects. In contrast, the CHO component of L-LPS should be oriented 
quite differently following binding to its receptor on the surface of macro-
phages. Both recognition of L-LPS and its CHO component should be class 
11 MHC (la) restricted. Clearly, like L-LPS, any antigen recognized by 
appropriate T cells and present in appropriate amounts on the infected 
macrophage surface should serve as a target of aggressive T cell-mediated 
attack. If T-cell receptors stabilize associations between antigen and la 
molecules at the cell surface, then amounts of lipophilic antigen at the 
infected macrophage surface (in the absence of any real affinity of most 
antigens for la) will be the critical factor. 
The nature of disease-promoting immunity remains unknown. Antibodies 
appear to play no role in either resistance or disease-promoting immunity. 
An hypothesis we favour at the moment is that CHO recognition by IFN--y 
producing T cells at the surface of uninfected macrophages in lesions increases 
the expression of the macrophage receptors to which CHO binds in the 
process of 'facilitated phagocytosis' of leishmania. This increased display of 
receptors enables parasites released from destroyed macrophages to gain 
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entry quickly and thereby facilitates spread of infection. Clearly, little more 
can be gained from speculation in the absence of (a) structural data on the 
L-LPS and its carbohydrate fragment(s) released by phospholipase treatment, 
(b) T -cell clones with specificity for these antigens and (c) clonal analyses of 
T-cell populations in immunized mice of various genotypes using defined 
antigens. 
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DISCUSSION - Chaired by Dr J. B. Robbins 
HANDMAN: Our problems began, though, when we tried to induce the same 
type of protection using the water-soluble carbohydrate antigen alone. In 
this example we used genetically resistant mice which develop a lesion that 
will eventually heal so the uninjected mice or the ones injected with the 
adjuvant alone eventually heal. However, mice that were immunized or 
vaccinated with the carbohydrate in Freund's complete adjuvant, were not 
only not protected from disease but, in fact, the disease was exacerbated. I 
could put forward several hypotheses for what causes this peculiar type of 
immune response but I won't because we have no evidence for any of them 
and this is where I would like to get some feedback from you people who 
have worked with carbohydrate antigens for a long time. I think that it may 
be a matter of antigen presentation - that the glycolipid antigen is anchored 
in the membrane of the antigen-presenting cell in such a way that it can 
interact with the host-histocompatibility antigen in a way that will then induce 
a T-cell protective immune response, whereas the carbohydrate alone may 
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interact with the initial ligand, the molecule it normally binds to, but then it 
probably doesn't interact with class 11 antigen in the same way that the 
glycolipid does. All of this though is speculation and we really don't under-
stand it. What we do understand is that we will not rush into human vacci-
nation trials until we know how to make a very stable preparation to ensure 
that we will induce the appropriate immune response. 
ADA: If you immunize your mice with the soluble carbohydrates and then 
immunize with the lipid, what happens? 
HANDMAN: We are doing these experiments now in both directions to see if 
the carbohydrate overrides protection or if the glycolipid overrides 
suppression. 
ADA: One possibility might be that you are causing tolerance to suppressor-
T cells, you are activating suppressor-T cells by giving the free carbohydrate. 
Now, if that were the case, if you gave the free carbohydrate, then treated 
with cyclophosphamide to get rid of those suppressor-T cells then your mice 
might become more responsive to the glycolipid. I would think that if you 
did those two sets of experiments you might get an indication whether that 
was what was happening. 
HANDMAN: Well, Graham Mitchell is doing this experiment now and we 
should know soon. 
HOOKE: Have you thought about incorporating the glycolipid into liposomes 
and looking at the immune response to that? 
HANDMAN: Yes. In fact my very first experiment was to use a lipid adjuvant 
called Lipovant, sold by Accurate Biochemicals in the USA, which is egg 
lecitin and, in fact, I found that the adjuvant alone, or the liposomes alone, 
exacerbated the disease and we have not used them since, but we will try 
and prepare our own liposomes. 
KABAT: I would like to say, I will say more about it this afternoon, that 
Charles Wood and Eric Lai in my laboratory have been quite successful in 
getting antibodies to the isomaltose oligosaccharides coupled to stearylamine, 
so that you could take your recovered carbohydrate, couple it to something 
like stearylamine and make another type of glycolipid which we found to be 
a very good antigen, which seems to be thymus independent. 
MORENO: Just for clarification, did you follow the antibody titres in those 
animals immunized with soluble polysaccharide in complete Freund's 
adjuvant? 
HANDMAN: Yes. I must stress though, that the antibodies are not believed to 
play a role in protection in cutaneous leishmaniasis, it is a T-cell mediated 
type of protection, but I did follow the antibody titres and the mice made 
no antibodies whatsoever, whereas they did make antibodies when immu-
nized with the glycolipid. 
MAKELA, Helena: In one of your slides you had in parenthesis an indication 
that this glycolipid antigen would also be active as a virulence factor within 
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the macrophages. I wonder whether you have any evidence of the mechanism 
of this activity? 
HANDMAN: We have been trying to produce parasite mutants that lack this 
molecule and we found one such parasite which is taken up by macrophages, 
probably by a different mechanism, and is killed inside macrophages very 
rapidly. There are two possibilities and I can't distinguish between them. 
One is that a parasite which has this glycolipid molecule on its surface will 
interact with a set of receptors on macrophages which will target it into a 
compartment in the macrophage where it can survive. The parasite that does 
not have this antigen on the surface will interact with a different set of ligands 
on the macrophage and will end up in a different compartment and be killed, 
let us say by lysosomal enzymes for example. The other possibility is that 
parasites with or without this coat will end up in the same compartment, but 
this glycolipid protects them from killing by lysosomal enzymes. I cannot, at 
the moment, distinguish between them, but when I took these mutant para-
sites and incorporated into their membrane the purified lipids from the wild-
type parasite, they survived much better in macrophages. So I think that this 
molecule is also involved in survival, I am still not sure exactly at what level. 
MAKELA, Helena: We have made rather similar observations, still at a prelimi-
nary stage, with Salmonella bacteria, a bacterial parasite which, however, 
lives in the same compartment in the macrophages as does the Leishmania, 
and obeys very much the same rules. We have looked at mutants that are 
devoid of a glycolipid antigen called the enterobacterial common antigen; to 
our great surprise they were very much more sensitive to the intracellular 
compartment than the normal ones and we are at the moment in the process 
of finding out what the mechanism of that is. 
HANDMAN: It would be intriguing if they were targeted to a different compart-
ment. There was a time when we used to believe that a lysosome is a 
lysosome is a lysosome, now I think there is more and more evidence that 
there are various acidic compartments and they are not all the same. 
SODERSTROM: Did you look at the presence of these receptors also in the 
Langerhans cells, in the skin? 
HANDMAN: No, we have not yet. 
SUTHERLAND: You mentioned a disaccharide repeating unit. Can you give us 
any indication of either the composition or the structure of this unit? 
HANDMAN: Well these are not my own data. It is a preliminary personal 
communication from Sam Turco so I would like to be very careful. He thinks 
that, in the case of Leishmania donovani - the parasite causing visceral 
disease in man, it is a (mannose ([3-1.4) galactose) disaccharide unit which 
is phosphodiester-linked. But I can't say any more. 
ROTTA: I might have missed this, but I am wondering whether you looked in 
your immunized animals for cell-mediated immunity reactions? 
HANDMAN: No, we have not looked at the mechanism which induces host 
40 TOWARDS BETTER CARBOHYDRATE VACCINES 
protection in mice vaccinated with the lipid. We know that T cells from these 
mice respond to the glycolipid in vitro. We are now in the process of making 
T-celllines from these mice, but we haven't actually done any in vivo exper-
iments yet. 
